|
[1]Afione SA, Conrad CK, Kearns WG, Chunduru S, Adams R, Reynolds TC, Guggino WB, Cutting GR, Carter BJ, Flotte TR. 1996. In vivo model of adenoassociated virus vector persistence and rescue. J Virol. 70(5):3235–41.
[2]Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, Scaramuzza S, Andolfi G, Mirolo M, Brigida I, Tabucchi A, Carlucci F, Eibl M, Aker M, Slavin S, Al-Mousa H, Al Ghonaium A, Ferster A, Duppenthaler A, Notarangelo L, Wintergerst U, Buckley RH, Bregni M, Marktel S, Valsecchi MG, Rossi P, Ciceri F, Miniero R, Bordignon C, Roncarolo MG. 2009. Gene therapy for immuno-deficiency due to adenosine deaminase deficiency. N Engl J Med. 360(5):447–58.
[3]Akli S, Caillaud C, Vigne E, Stratford-Perricaudet LD, Poenaru L, Perricaudet M, Kahn A, Peschanski MR. 1993. Transfer of a foreign gene into the brain using adenovirus vectors. Nat Genet. 3(3):224–8.
[4]Alba R, Bosch A, Chillon M. 2005. Gutless adenovirus: last-generation adenovirus for gene therapy. Gene Ther. 12(Suppl 1):S18–27.
[5]Alexander WA, Moss B, Fuerst TR. 1992. Regulated expression of foreign genes in vaccinia virus under the control of bacteriophage T7 RNA polymerase and the Escherichia coli lac repressor. J Virol. 66(5):2934–42.
[6]Aliño SF, Herrero MJ, Noguera I, Dasí F, Sánchez M. 2007. Pig liver gene therapy by noninvasive interventionist catheterism. Gene Ther. 14(4):334–43.
[7]Arad U, Zeira E, El-Latif MA, Mukherjee S, Mitchell L, Pappo O, Galun E, Oppenheim A. 2005. Liver-targeted gene therapy by SV40-based vectors using the hydrodynamic injection method. Hum Gene Ther. 16(3):361–71.
[8]Arnberg N. 2009. Adenovirus receptors: implications for tropism, treatment and targeting. Rev Med Virol. 19(3):165–78.
[9]Arnold GS, Sasser AK, Stachler MD, Bartlett JS. 2006. Metabolic biotinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol Ther. 14(1):97–106.
[10]Avery OT, MacLeod CM, McCarty M. 1979. Studies on the chemical nature of the substance inducing transformation of pneumococcal types: inductions of transformation by a deoxyribonucleic acid fraction isolated from pneumococcus type III. J Exp Med. 149:297–326.
[11]Avrameas A, Ternynck T, Nato F, Buttin G, Avrameas S. 1998. Polyreactive anti-DNA monoclonal antibodies and a derived peptide as vectors for the intracytoplasmic and intranuclear translocation of macromolecules. Proc Natl Acad Sci U S A. 95(10):5601–6.
[12]Bakker AC, Van de Loo FA, Joosten LA, Bennink MB, Arntz OJ, Dmitriev IP, Kashentsera EA, Curiel DT, van den Berg WB. 2001. A tropism-modified adenoviral vector increased the effectiveness of gene therapy for arthritis. Gene Ther. 8(23):1785–93.
[13]Balicki D, Beutler E. 1997. Histone H2A significantly enhances in vitro DNA transfection. Mol Med. 3(11):782–7.
[14]Balicki D, Putnam CD, Scaria PV, Beutler E. 2002. Structure and function correlation in histone H2A peptide-mediated gene transfer. Proc Natl Acad Sci U S A. 99(11):7467–71.
[15]Bangari DS, Mittal SK. 2006. Development of nonhuman adenoviruses as vaccine vectors. Vaccine. 24(7):849–62.
[16]Bangham AD, Standish MM, Watkins JC. 1965. Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 13(1):238–52.
[17]Bao S, Thrall BD, Gies RA, Miller DL. 1998. In vivo transfection of melanoma cells by lithotripter shock waves. Cancer Res. 58(2):219–21.
[18]Bao S, Thrall BD, Miller DL. 1997. Transfection of a reporter plasmid into cultured cells by sonoporation in vitro. Ultrasound Med. Biol. 23(6):953–9.
[19]Barquinero J, Eixarch H, Pérez-Melgosa M. 2004. Retroviral vectors: new applications for an old tool. Gene Ther. 11 (Suppl 1):S3–9.
[20]Barreiro O, Aguilar Rio J, Tejera E, Megías D, de Torres-Alba F, Evangelista A, Sánchez-Madrid F. 2009. Specific targeting of human inflamed endothelium and in situ vascular tissue transfection by the use of ultrasound contrast agents. JACC Cardiovasc Imaging. 2(8):997–1005.
[21]Bartlett JS, Kleinschmidt J, Boucher RC, Samulski RJ. 1999. Targeted adenoassociated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab′gamma) 2 antibody. Nat Biotechnol. 17(2):181–6
[22]Bauer TR Jr, Allen JM, Hai M, Tuschong LM, Khan IF, Olson EM, Adler RL, Burkholder TH, Gu YC, Russell DW, Hickstein DD. 2008. Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors. Nat Med. 14(1):93–7.
[23]Bekeredjian R, Chen S, Frenkel PA, Grayburn PA, Shohet RV. 2003. Ultrasound-targeted microbubble destruction can repeatedly direct highly specific plasmid expression to the heart. Circulation. 108(8):1022–6.
[24]Bekeredjian R, Grayburn PA, Shohet RV. 2005. Use of ultrasound contrast agents for gene or drug delivery in cardiovascular medicine. J Am Coll Cardiol. 45(3):329–35.
[25]Bett AJ, Haddara W, Prevec L, Graham FL. 1994. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA. 91(19):8802–6.
[26]Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, Shearer G, Chang L, Chiang Y, Tolstoshev P, Greenblatt JJ, Rosenberg SA, Klein H, Berger M, Mullen CA, Ramsey WJ, Muul L, Morgan RA, Anderson WF. 1995. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 270(5235):475–80.
[27]Blömer U, Naldini L, Verma IM, Trono D, Gage FH. 1996. Applications of gene therapy to the CNS. Hum Mol Genet. 5(spec no.):1397–404.
[28]Bodles-Brakhop AM, Heller R, Draghia-Akli R. 2009. Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments. Mol Ther. 17(4):585–92.
[29]Bouard D, Alazard-Dany D, Cosset FL. 2009. Viral vectors: from virology to transgene expression. Br J Pharmacol. 157(2):153–65.
[30]Boussif O, Lezoualc’h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, Behr JP. 1995. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A. 92(16):7297–301.
[31]Brunetti-Pierri N, Palmer DJ, Mane V, Finegold M, Beaudet AL, Ng P. 2005. Increased hepatic transduction with reduced systemic dissemination and proinflammatory cytokines following hydrodynamic injection of helperdependent adenoviral vectors. Mol Ther. 12(1):99–106.
[32]Brunetti-Pierri N, Stapleton GE, Palmer DJ, Zuo Y, Mane VP, Finegold MJ, Beaudet AL, Leland MM, Mullins CE, Ng P. 2007. Pseudo-hydrodynamic delivery of helper-dependent adenoviral vectors into non-human primates for liver-directed gene therapy. Mol Ther. 15(4):732–40.
[33]Buch PK, Bainbridge JW, Ali RR. 2008. AAV-mediated gene therapy for retinal disorders: from mouse to man. Gene Ther. 15(11):849–57.
[34]Buning H, Perabo L, Coutelle O, Quadt-Humme S, Hallek M. 2008. Recent developments in adeno-associated virus vector technology. J Gene Med. 10(7):717–33.
[35]Burcin MM, Schiedner G, Kochanek S, Tsai SY, O’Malley BW. 1999. Adenovirus-mediated regulable target gene expression in vivo. Proc Natl Acad Sci USA. 96(2):355–60.
[36]Burton EA, Bai Q, Goins WF, Glorioso JC. 2002. Replication-defective genomic herpes simplex vectors: design and production. Curr Opin Biotechnol. 13(5):424–8.
[37]Butow RA, Fox TD. 1990. Organelle transformation: shoot first, ask questions later. Trends Biochem Sci 15(12):465–8.
[38]Byrnes AP, Rusby JE, Wood MJ, Charlton HM. 1995. Adenovirus gene transfer causes inflammation in the brain. Neuroscience 66(4):1015–24.
[39]Calmon MF, de Souza AT, Candido NM, Raposo MI, Taboga S, Rahal P, Nery JG. 2012. A systematic study of transfection efficiency and cytotoxicity in HeLa cells using iron oxide nanoparticles prepared with organic and inorganic bases. Colloids and Surf B: Biointerfaces 100:177– 84.
[40]Carroll MW, Moss B. Poxviruses as expression vectors. 1997. Curr. Opin .Biotechnol. 8(5):573–7.
[41]Cassaday RD, Sondel PM, King DM, Macklin MD, Gan J, Warner TF, Zuleger CL, Bridges AJ, Schalch HG, Kim KM, Hank JA, Mahvi DM, Albertini MR. 2007. A phase I study of immunization using particlemediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients. Clin Cancer Res. 13(2 Pt1):540–9.
[42]Cearley CN, Vandenberghe LH, Parente MK, Carnish ER, Wilson JM, Wolfe JH. 2008. Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain. Molec Ther. 16(10):1710–8.
[43]Chakravarty P, Qian W, El-Sayed MA, Prausnitz MR. 2010. Delivery of molecules into cells using carbon nanoparticles activated by femtosecond laser pulses. Nat Nanotechnol. 5(8):607–11.
[44]Check E. 2003. Second cancer case halts gene-therapy trials. Nature. 421(6921):305.
[45]Chemin I, Moradpour D, Wieland S, Offensperger WB, Walter E, Behr JP, Blum HE. 1998. Liver-directed gene transfer: a linear polyethlenimine derivative mediates highly efficient DNA delivery to primary hepatocytes in vitro and in vivo. J Viral Hepat. 5(6):369–75.
[46]Chen L, Zhu F, Li J, Lu H, Jiang H, Sarkar R, Arruda VR, Wang J, Zhao J, Pierce GF, Ding Q, Wang X, Wang H, Pipe SW, Liu XQ, Xiao X, Camire RM, Xiao W. 2007. The enhancing effects of the light chain on heavy chain secretion in split delivery of factor VIII gene. Mol Ther. 15(10):1856–62.
[47]Chen N, Zhang Q, Yu YA, Stritzker J, Brader P, Schirbel A, Samnick S, Serganova I, Blasberg R, Fong Y, Szalay AA. 2009. A novel recombinant vaccinia virus expressing the human norepinephrine transporter retains oncolytic potential and facilitates deep-tissue imaging. Mol Med. 15(5-6):144-151.
[48]Chen S, Ding JH, Bekeredjian R, Yang BZ, Shohet RV, Johnston SA, Hohmeier HE, Newgard CB, Grayburn PA. 2006. Efficient gene delivery to pancreatic islets with ultrasonic microbubble destruction technology. Proc Natl Acad Sci U S A. 103(22):8469–74.
[49]Choate KA, Khavari PA. 1997. Direct cutaneous gene delivery in a human genetic skin disease. Hum Gene Ther. 8(14):1659–65.
[50]Condiotti R, Curran MA, Nolan GP, Giladi H, Ketzinel-Gilad M, Gross E, Galun E. 2004. Prolonged liver-specific transgene expression by a nonprimate lentiviral vector. Biochem Biophys Res Commun. 320(3):998–1006.
[51]Coura RS, Nardi NB. 2007. The state of the art of adeno-associated virus-based vectors in gene therapy. Virol J. 4:99.
[52]Cox WI, Tartaglia J, Paoletti E. 1992. Poxvirus recombinants as live vaccines. In Recombinant Poxviruses (Binns, M. M. and Smith, G. L., eds.) CRC Press, Boca Raton 123–162.
[53]Cregan SP, MacLaurin J, Gendron TF, Callaghan SM, Park DS, Parks RJ, Graham FL, Morley P, Slack RS. 2000. Helper-dependent adenovirus vectors: their use as a gene delivery system to neurons. Gene Ther. 7(14):1200–9.
[54]Cronin J, Zhang XY, Reiser J. 2005. Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther. 5(4):387–98.
[55]Cuchet D, Potel C, Thomas J, Epstein AL. 2007. HSV-1 amplicon vectors: a promising and versatile tool for gene delivery. Expert Opin Biol Ther. 7(7):975–95.
[56]Cullen BR, Garrett ED. 1992. A comparison of regulatory features in primate lentiviruses. AIDS Res. Hum. Retroviruses 8(3):387–393.
[57]Dalby B, Cates S, Harris A, Ohki EC, Tilkins ML, Price PJ, Ciccarone VC. 2004. Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications. Methods 33(2):95–103.
[58]Daniel R, Smith JA. 2008. Integration site selection by retroviral vectors: molecular mechanism and clinical consequences. Hum Gene Ther. 19(6):557–68.
[59]Davidson BL, Allen ED, Kozarsky KF, Wilson JM, Roessler BJ. 1993. A model system for in vivo gene transfer into the central nervous system using an adenoviral vector. Nat Genet. 3(3):219–23
[60]Davidson BL, Stein CS, Heth JA, Martins I, Kotini RM, Derksen TA, Zabner J, Ghodsi A, Chiorini JA. 2000. Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci USA. 97(7):3428–32.
[61]Davies MV, Kaufman RJ. 1992. Internal translation initiation in the design of improved expression vectors. Curr Opin Biotech. 3(5):512–7.
[62]Daya S, Berns KI. 2008. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev. 21(4):583–93.
[63]Dedieu JF, Vigne E, Torrent C, Jullien C, Mahfouz I, Caillaud JM, Aubailly N, Orsini C, Guillaume JM, Opolon P, Delaere P, Perricaudet M, Yeh P. 1997. Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. J Virol. 71(6):4626–37.
[64]Delenda C. 2004. Lentiviral vectors: optimization of packaging, transduction and gene expression. J Gene Med. 6 (Suppl 1):S125–38.
[65]DePolo NJ, Reed JD, Sheridan PL, Townsend K, Sauter SL, Jolly DJ, Dubensky TW Jr. 2000. VSV-G pseudotyped lentiviral vector particles produced in human cells are inactivated by human serum. Mol Ther. 2(3):218–22.
[66]Dimitrov DS, Norwood D, Stantchev TS, Feng Y, Xiao X, Broder CC. 1999. A mechanism of resistance to HIV-1 entry: inefficient interactions of CXCR4 with CD4 and gp120 in macrophages. Virology 259(1):1–6.
[67]Dobson J. 2006. Gene therapy progress and prospects: magnetic nanoparticle-based gene delivery. Gene Ther. 13(4):283–7.
[68]Doenecke A, Kromer A, Scherer MN, Schlitt HJ, Geissler EK. 2010. AAV plasmid DNA simplifies liver-directed in vivo gene therapy: comparison of expression levels after plasmid DNA-, adeno-associated virus- and adenovirus-mediated liver transfection. J Gene Med. 12(10):810–7.
[69]Drape RJ, Macklin MD, Barr LJ, Jones S, Haynes JR, Dean HJ. 2006. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine. 24(21):4475–81.
[70]Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D, Naldini L. 1998. A third-generation lentivirus vector with a conditional packaging system. J Virol. 72(11):8463–71.
[71]Durcan N, Murphy C, Cryan SA. 2008. Inhalable siRNA: potential as a therapeutic agent in the lungs. Mol Pharm. 5(4):559–66.
[72]Earl P, Moss B. 1991. Generation of recombinant vaccinia viruses. Current Protocols in Molecular Biology, Wiley-Interscience, New York 16.15.1–16.18.10.
[73]Eastman SJ, Baskin KM, Hodges BL, Chu Q, Gates A, Dreusicke R, Anderson S, Scheule RK. 2002. Development of catheter-based procedures for transducing the isolated rabbit liver with plasmid DNA. Hum Gene Ther. 13(17):2065–77.
[74]El-Aneed A. 2004. An overview of current delivery systems in cancer gene therapy. J Control Release. 94(1):1– 14.
[75]Elroy-Stein O, Moss B. 1992. Gene expression using the vaccinia virus/T7 RNA polymerase hybrid system. Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley Interscience 16.19.1–16.19.12.
[76]Engelhardt JF, Ye X, Doranz B, Wilson JM. 1994. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci U S A. 91(13):6196–200.
[77]Epstein AL. 2009. Progress and prospects: biological properties and technological advances of herpes simplex virus type 1-based amplicon vectors. Gene Ther. 16(6):709–15.
[78]Erbacher P, Zou S, Bettinger T, Steffan AM, Remy JS. 1998. Chitosan-based vector/DNA complexes for gene delivery: biophysical characteristics and transfection ability. Pharm Res. 15(9):1332–9.
[79]Erlwein O, McClure MO. 2010. Progress and prospects: foamy virus vectors enter a new age. Gene Ther. 17(12):1423–9.
[80]Fabre JW, Grehan A, Whitehorne M, Sawyer GJ, Dong X, Salehi S, Eckley L, Zhang X, Seddon M, Shah AM, Davenport M, Rela M. 2008. Hydrodynamic gene delivery to the pig liver via an isolated segment of the inferior vena cava. Gene Ther. 15(6):452–62.
[81]Favard C, Dean DS, Rols MP. 2007. Electrotransfer as a nonviral method of gene delivery. Curr Gene Ther. 7(1):67–77.
[82]Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielsen M. 1987. Lipofection: a highly efficient, lipid-mediated DNA transfection procedure. Proc Natl Acad Sci U S A. 84(21):7413–7.
[83]Fenner F. 1992. Vaccinia virus as a vaccine, and poxvirus pathogenesis. In Recombinant Poxviruses (Binns, M. M. and Smith, G. L., eds.) CRC Press, Boca Raton, 1–43.
[84]Flexner C, Moss B. 1997. Vaccinia virus as a live vector for expression of immunogens. 2nd ed. New Generation Vaccines, Marcel Dekker, New York 297–314.
[85]Friedman GK, Pressey JG, Reddy AT, Markert JM, Gillespie GY. 2009. Herpes simplex virus oncolytic therapy for pediatric malignancies. Mol Ther. 17(7):1125–35.
[86]Fu H, Muenzer J, Samulski RJ, Breese G, Sifford J, Zeng X, McCarty DM. 2003. Self-complementary adeno-associated virus serotype 2 vector: global distribution and broad dispersion of AAVmediated transgene expression in mouse brain. Molec Ther. 8(6):911–7.
[87]Fuerst TR, Earl PL, Moss B. 1987. Use of hybrid vaccinia virus-T7 RNA polymerase system for expression of target genes. Mol Cell Biol. 7(7):2538–44.
[88]Fuerst TR, Fernandez MP, Moss B. 1989. Transfer of the inducible lac repressor/operator system from Escherichia coli to a vaccinia virus expression vector. Proc Natl Acad Sci U S A. 86(8):2549–2553.
[89]Fuerst TR, Niles EG, Studier FW, Moss B. 1986. Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc Natl Acad Sci U S A. 83(21):8122–8126.
[90]Glorioso JC, Fink DJ. 2009. Herpes vector-mediated gene transfer in the treatment of chronic pain. Mol Ther. 17(1):13–8.
[91]Glover DJ, Lipps HJ, Jans DA. 2005. Towards safe, non-viral therapeutic gene expression in humans. Nat Rev Genet 6(4):299–310.
[92]Goula D, Remy JS, Erbacher P, Wasowicz M, Levi G, Abdallah B, Demeneix BA. 1998. Size, diffusibility and transfection performance of linear PEI/DNA complexes in the mouse central nervous system. Gene Ther. 5(5):712–7.
[93]Graham FL, van dee Eb A J. 1973.Transformation of rat cells by DNA of human adenovirus 5. Virology 54(2):536-9.
[94]Graham FL, Smiley J, Russell WC, Nairn R. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol. 36(1):59–74.
[95]Green JJ, Shi J, Chiu E, Leshchiner ES, Langer R, Anderson DG. 2006. Biodegradable polymeric vectors for gene delivery to human endothelial cells. Bioconjugate Chem. 17(5):1162-9.
[96]Guo H, Leung JC, Chan LY, Tsang AW, Lam MF, Lan HY, Lai KN. 2007. Ultrasound-contrast agent mediated naked gene delivery in the peritoneal cavity of adult rat. Gene Ther. 14(24):1712–20.
[97]Habib NA, Ding SF, el-Masry R, Mitry RR, Honda K, Michail NE, Dalla Serra G, Izzi G, Greco L, Bassyouni M, el-Toukhy M, Abdel-Gaffar Y. 1996. Preliminary report: the short-term effects of direct p53 DNA injection in primary hepatocellular carcinomas. Cancer Detect Prev. 20(2):103–7.
[98]Hacein-Bey-Abina S, Hauer J, Lim A, Picard C, Wang GP, Berry CC, Martinache C, Rieux-Laucat F, Latour S, Belohradsky BH, Leiva L, Sorensen R, Debré M, Casanova JL, Blanche S, Durandy A, Bushman FD, Fischer A, Cavazzana-Calvo M. 2010. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 363(4):355–64.
[99]Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP, Thrasher AJ, Wulffraat N, Sorensen R, Dupuis-Girod S, Fischer A, Davies EG, Kuis W, Leiva L, Cavazzana-Calvo M. 2002. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 346(16):1185–93.
[100]Haensler J, Szoka FC Jr. 1993. Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. Bioconjug Chem. 4(5):372–9.
[101]Hahn P, Scanlan E. 2010. Gene delivery into mammalian cells: An overview on existing approaches employed in vitro and in vivo. Top Curr Chem. 296:1-13.
[102]Harding TC, Geddes BJ, Murphy D, Knight D, Uney JB. 1998. Switching transgene expression in the brain using an adenoviral tetracycline-regulatable system. Nat Biotechnol. 16(6):553–5.
[103]Hartikka J, Sawdey M, Cornefert-Jensen F, Margalith M, Barnhart K, Nolasco M, Vahlsing HL, Meek J, Marquet M, Hobart P, Norman J, Manthorpe M. 1996. An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hum Gene Ther. 7(10):1205–17.
[104]Havenga MJ, Lemckert AA, Ophorst OJ, van Meijer M, Germeraad WT, Grimbergen J, van Den Doel MA, Vogels R, van Deutekom J, Janson AA, de Bruijn JD, Uytdehaag F, Quax PH, Logtenberg T, Mehtali M, Bout A. 2002. Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J Virol. 76(9):4612–20.
[105]Hayashi S, Mizuno M, Yoshida J, Nakao A. 2009. Effect of sonoporation on cationic liposome-mediated IFNbeta gene therapy for metastatic hepatic tumors of murine colon cancer. Cancer Gene Ther. 16(8):638–43.
[106]He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. 1998. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A. 95(5):2509–14.
[107]Heller LC, Ugen K, Heller R. 2005. Electroporation for targeted gene transfer. Expert Opin Drug Deliv. 2(2):255–68.
[108]Heller R, Jaroszeski MJ, Glass LF, Messina JL, Rapaport DP, DeConti RC, Fenske NA, Gilbert RA, Mir LM, Reintgen DS. 1996. Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy. Cancer. 77(5):964–71.
[109]Hermens WT, Verhaagen J. 1998. Viral vectors, tools for gene transfer in the nervous system. Prog Neurobiol. 55(4):399–432.
[110]Herweijer H, Wolff JA. 2007. Gene therapy progress and prospects: hydrodynamic gene delivery. Gene Ther. 14(2):99–107.
[111]Hickman MA, Malone RW, Lehmann-Bruinsma K, Sih TR, Knoell D, Szoka FC, Walzem R, Carlson DM, Powell JS. 1994. Gene expression following direct injection of DNA into liver. Hum Gene Ther. 5(12):1477–83.
[112]Hou C-C, Wang W, Huang XR, Fu P, Chen TH, Sheikh-Hamad D, Lan HY. 2005. Ultrasound-microbubble-mediated gene transfer of inducible Smad7 blocks transforming growth factor-beta signaling and fibrosis in rat remnant kidney. Am J Pathol. 166(3):761–71.
[113]Howarth JL, Glover CP, Uney JB. 2009. HSP70 interacting protein prevents the accumulation of inclusions in polyglutamine disease. J Neurochem. 108(4):945–51.
[114]Howarth JL, Kelly S, Keasey MP, Glover CP, Lee YB, Mitrophanous K, Chapple JP, Gallo JM, Cheetham ME, Uney JB. 2007. Hsp40 molecules that target to the ubiquitin-proteasome system decrease inclusion formation in models of polyglutamine disease. Mol Ther. 15(6):1100–5.
[115]Howarth JL, Lee YB, Uney JB. 2010. Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic manipulation of cells). Cell Biol Toxicol. 26(1):1–20.
[116]Hsu CYM, Uludağ H. 2012. Cellular uptake pathways of lipid-modified cationic polymers in gene delivery to primary cells. Biomaterials 33:7834-7848.
[117]Huber PE, Jenne J, Debus J, Wannenmacher MF, Pfisterer P. 1999. A comparison of shock wave and sinusoidal-focused ultrasound-induced localized transfection of HeLa cells. Ultrasound Med Biol. 25(9):1451–7.
[118]Hynynen K, McDannold N, Martin H, Jolesz FA, Vykhodtseva N. 2003. The threshold for brain damage in rabbits induced by bursts of ultrasound in the presence of an ultrasound contrast agent (Optison). Ultrasound Med Biol. 29(3):473–81.
[119]Kafri T, van PH, Gage FH, Verma IM. 2000. Lentiviral vectors: regulated gene expression. Mol Ther. 1(6):516–21.
[120]Kamimura K, Guisheng Z, Liu D. 2010. Image-guided, intravascular hydrodynamic gene delivery to skeletal muscle in pigs. Mol Ther. 18(1):93–100.
[121]Kamimura K, Suda T, Xu W, Zhang G, Liu D. 2009. Image-guided, lobe-specific hydrodynamic gene delivery to swine liver. Mol Ther. 17(3):491–9.
[122]Kamimura K, Suda T, Zhang G, Liu D. 2011. Advances in gene delivery systems. Pharmaceut Med. 25(5):293–306.
[123]Karra D, Dahm R. 2010. Transfection techniques for neuronal cells. The Journal of Neuroscience 30(18):6171–7.
[124]Kaufman RJ. 2000. Overview of vector design for mammalian gene expression. Mol Biotechnol. 16(2):151-60.
[125]Kaur T, Slavcev RA, Wettig SD. 2009. Addressing the challenge: current and future directions in ovarian cancer therapy. Curr Gene Ther. 9(6):434–58.
[126]Kim D, Hoory T, Monie A, Ting JP, Hung CF, Wu TC. 2008. Enhancement of DNA vaccine potency through coadministration of CIITA DNA with DNA vaccines via gene gun. J Immunol. 180(10):7019–27.
[127]Kim HJ, Greenleaf JF, Kinnick RR, Bronk JT, Bolander ME. 1996. Ultrasound-mediated transfection of mammalian cells. Hum Gene Ther. 7(11):1339–46.
[128]Kim JA, Lee WG, Jung NC. 2010. Enhanced electro-mediated gene delivery using carrier genes. Bioelectrochemistry 78(2):186–190.
[129]Kim TK, Eberwine JH. 2010. Mammalian cell transfection: the present and the future. Anal Bioanal Chem. 397(8):3173–8.
[130]Kim VN, Mitrophanous K, Kingsman SM, Kingsman AJ. 1998. Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J Virol. 72(1):811–6.
[131]Kingston RE. 2003. Introduction of DNA into Mammalian Cells. Current Protocols in Molecular Biology. 9.0.1-9.0.5.
[132]Klein RM, Wolf ED, Wu R, Sanford JC. 1992. High-velocity microprojectiles for delivering nucleic acids into living cells: 1987. Biotechnology. 24:384–6.
[133]Kobayashi N, Rivas-Carrillo JD, Soto-Gutierrez A, Fukazawa T, Chen Y, Navarro-Alvarez N, Tanaka N. 2005. Gene delivery to embryonic stem cells. Birth Defects Research (Part C) 75(1):10–18.
[134]Koczot FJ, Carter BJ, Garon CF, Rose JA. 1973. Self-complementarity of terminal sequences within plus or minus strands of adenovirus-associated virus DNA. Proc Natl Acad Sci U S A. 70(1):215–9.
[135]Kodama T, Aoi A, Watanabe Y, Horie S, Kodama M, Li L, Chen R, Teramoto N, Morikawa H, Mori S, Fukumoto M. 2010. Evaluation of transfection efficiency in skeletal muscle using nano/microbubbles and ultrasound. Ultrasound Med Biol. 36(7):1196–205.
[136]Konstan MW, Davis PB, Wagener JS, Hilliard KA, Stern RC, Milgram LJ, Kowalczyk TH, Hyatt SL, Fink TL, Gedeon CR, Oette SM, Payne JM, Muhammad O, Ziady AG, Moen RC, Cooper MJ. 2004. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Hum Gene Ther. 15(12):1255–69.
[137]Lee D, Upadhye K, Kumta PN. 2012. Nano-sized calcium phosphate (CaP) carriers for non-viral gene delivery. Materials Science and Engineering: B 177(3):289–302.
[138]Lee LK, Williams CL, Devore D, Roth CM. 2006. Poly(propylacrylic acid) enhances cationic lipid-mediated delivery of antisense oligonucleotides. Biomacromolecules. 7(5):1502–8.
[139]Lee RJ, Huang L. 1996. Folate-targeted, anionic liposome-entrapped polylysine-condensed DNA for tumor cell-specific gene transfer. J Biol Chem. 271(14):8481–7.
[140]Leitner WW, Ying H, Restifo NP. 2000. DNA and RNA-based vaccines: principles, progress and prospects. Vaccine 18(9-10):765-77.
[141]Lewis PF, Emerman M. 1994. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J Virol. 68(1):510–6.
[142]Li S, Huang L. 1997. In vivo gene transfer via intravenous administration of cationic lipid-protamine-DNA (LPD) complexes. Gene Ther. 4(9):891–900.
[143]Liu D, Ren T, Gao X. 2003. Cationic transfection lipids. Curr Med Chem. 10(14):1307–15.
[144]Liu F, Song Y, Liu D. 1999. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 6(7):1258–66.
[145]Liu Y, Yang H, Sakanishi A. 2006. Ultrasound: Mechanical gene transfer into plant cells by sonoporation. Biotechnol Adv. 24(1):1–16.
[146]Lu QL, Liang H-D, Partridge T, Blomley MJ. 2003. Microbubble ultrasound improves the efficiency of gene transduction in skeletal muscle in vivo with reduced tissue damage. Gene Ther. 10(5):396–405.
[147]Lu X, Humeau L, Slepushkin V, Binder G, Yu Q, Slepushkina T, Chen Z, Merling R, Davis B, Chang YN, Dropulic B. 2004. Safe two-plasmid production for the first clinical lentivirus vector that achieves >99% transduction in primary cells using a one-step protocol. J Gene Med. 6(9):963–73.
[148]Mackett M, Smith GL, Moss B. 1982. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci U S A. 79(23):7415–9.
[149]Mackett M. 1991. Manipulation of vaccinia virus vectors. Gene Transfer and Expression Protocols 7:129–46.
[150]Manilla P, Rebello T, Afable C, Lu X, Slepushkin V, Humeau LM, Schonely K, Ni Y, Binder GK, Levine BL, MacGregor RR, June CH, Dropulic B. 2005. Regulatory considerations for novel gene therapy products: a review of the process leading to the first clinical lentiviral vector. Hum Gene Ther. 16(1):17–25.
[151]Manome Y, Nakamura M, Ohno T, Furuhata H. 2000. Ultrasound facilitates transduction of naked plasmid DNA into colon carcinoma cells in vitro and in vivo. Human Gene Therapy 11(11):1521–8.
[152]Manome Y, Nakayama N, Nakayama K, Furuhata H. 2005. Insonation facilitates plasmid DNA transfection into the central nervous system and microbubbles enhance the effect. Ultrasound Med Biol. 31(5):693–702.
[153]Markert JM, Parker JN, Buchsbaum DJ, Grizzle WE, Gillespie GY, Whitley RJ. 2006. Oncolytic HSV-1 for the treatment of brain tumours. Herpes.13(3):66–71.
[154]Marshall E. 1999. Gene therapy death prompts review of adenovirus vector. Science. 286(5448):2244–5.
[155]McCarty DM, Monahan PE, Samulski RJ. 2001. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 8(16):1248–54.
[156]Mehier-Humbert S, Guy RH. 2005. Physical methods for gene transfer: Improving the kinetics of gene delivery into cells. Adv Drug Deliv Rev. 57(5):733–53.
[157]Merdan T, Kopecek J, Kissel T. 2002. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Deliv Rev. 54(5):715–758.
[158]Mergia A, Heinkelein M. 2003. Foamy virus vectors. Curr Top Microbiol Immunol. 277:131–59.
[159]Miao CH, Brayman AA, Loeb KR, Ye P, Zhou L, Mourad P, Crum LA. 2005. Ultrasound enhances gene delivery of human factor IX plasmid. Hum Gene Ther. 16(7):893–905.
[160]Mintzer MA, Simanek EE. 2009. Nonviral vectors for gene delivery. Chem Rev. 109(2):259–302.
[161]Miyoshi H, Blömer U, Takahashi M, Gage FH, Verma IM. 1998. Development of a self-inactivating lentivirus vector. J Virol. 72(10):8150–7.
[162]Mizuguchi H, Kay MA. 1998. Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum Gene Ther. 9(17):2577–83.
[163]Monahan PE, Samulski RJ. 2000. AAV vectors: is clinical success on the horizon? Gene Ther. 7(1):24–30.
[164]Montier T, Benvegnu T, Jaffrès PA, Yaouanc JJ, Lehn P. 2008. Progress in cationic lipid-mediated gene transfection: a series of bio-inspired lipids as an example. Curr Gene Ther. 8(5):296–312.
[165]Morral N, O''Neal W, Zhou H, Langston C, Beaudet A. 1997. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors. Hum Gene Ther. 8(10):1275–86.
[166]Moss B. 1991. Vaccinia virus: A Tool for Research and Vaccine Development. Science 252(5013):1662–7.
[167]Moss B. 1993. Poxvirus vectors: cytoplasmic expression of transferred genes. Curr Opin Gen Dev. 3(1):86–90.
[168]Moss B. 1994. Replicating and host-restricted non- replicating vaccinia virus vectors for vaccine development. Dev Biol Stand. 82:55–63.
[169]Moss B. 1996. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci U S A. 93(21):11341–8.
[170]Murphy EA, Waring AJ, Haynes SM, Longmuir KJ. 2000. Compaction of DNA in an anionic micelle environment followed by assembly into phosphatidylcholine liposomes. Nucleic Acids Res. 28(15):2986–92.
[171]Muruve DA. 2004. The innate immune response to adenovirus vectors. Hum Gene Ther. 15(12):1157–66.
[172]Muzyczka N, Warrington KH Jr. 2005. Custom adeno-associated virus capsids: the next generation of recombinant vectors with novel tropism. Hum Gene Ther. 16(4):408–16.
[173]Mykhaylyk O, Antequera YS, Vlaskou D, Plank C. 2007. Generation of magnetic nonviral gene transfer agents and magnetofection in vitro. Nat Protoc. 2(10):2391–411.
[174]Nakashima M, Tachibana K, Iohara K, Ito M, Ishikawa M, Akamine A. 2003. Induction of reparative dentin formation by ultrasound-mediated gene delivery of growth/differentiation factor 11. Hum Gene Ther. 14(6):591–7.
[175]Naldini L, Blömer U, Gage FH, Trono D, Verma IM. 1996a. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A. 93:11382–8.
[176]Naldini L, Blömer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D. 1996b. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 272(5259):263–7.
[177]Nettelbeck DM. 2008. Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer. J Mol Med. 86(4):363–77.
[178]Neumann E, Schaefer-Ridder M, Wang Y, Hofschneider PH. 1982. Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J. 1(7):841–5.
[179]Ni TH, McDonald WF, Zolotukhin I, Melendy T, Waga S, Stillman B, Muzyczka N. 1998. Cellular proteins required for adenoassociated virus DNA replication in the absence of adenovirus coinfection. J Virol. 72(4):2777–87.
[180]Nicklin SA, Von Seggern DJ, Work LM, Pek DC, Dominiczak AF, Nemerow GR, Baker AH. 2001. Ablating adenovirus type 5 fiber- CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus. Mol Ther. 4(6):534–42.
[181]Nimesh S, Kumar R, Chandra R. 2006. Novel polyallylamine-dextran sulfate-DNA nanoplexes: highly efficient non-viral vector for gene delivery. Int J Pharm. 320(1-2):143–9.
[182]O’Brien J, Lummis SCR. 2002. An improved method of preparing microcarriers for biolistic transfection. Brain Res Brain Res Protoc. 10(1):12–5.
[183]O''Brien JA, Lummis SC. 2007. Diolistics: incorporating fluorescent dyes into biological samples using a gene gun. TRENDS in Biotechnology 25(11):530-34.
[184]Ohta S, Suzuki K, Tachibana K, Yamada G. 2003. Microbubble-enhanced sonoporation: efficient gene transduction technique for chick embryos. Genesis. 37(2):91–101.
[185]Okada N, Saito T, Masunaga Y, Tsukada Y, Nakagawa S, Mizuguchi H, Mori K, Okada Y, Fujita T, Hayakawa T, Mayumi T, Yamamoto A. 2001. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells. Cancer Res. 61(21):7913–9.
[186]Pacak CA, Sakai Y, Thattaliyath BD, Mah CS, Byrne BJ. 2008. Tissue specific promoters improve specificity of AAV9 mediated transgene expression following intra-vascular gene delivery in neonatal mice. Genet Vaccines Ther. 6:13.
[187]Pacchia AL, Adelson ME, Kaul M, Ron Y, Dougherty JP. 2001. An inducible packaging cell system for safe, efficient lentiviral vector production in the absence of HIV-1 accessory proteins. Virology. 282(1):77–86.
[188]Pagano JS, Vaheri A. 1965. Enhancement of infectivity of poliovirus RNA with DEAE dextran. Arch. Gesamte Virusforsch. 17(3-4):456-64.
[189]Palmer DJ, Ng P. 2005. Helper-dependent adenoviral vectors for gene therapy. Hum Gene Ther. 16(1):1–16.
[190]Panicali D, Paoletti E. 1982. Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci U S A. 79(16):4927–31.
[191]Paoletti E. 1996. Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci U S A. 93(21):11349–53.
[192]Pardridge WM. 2008. Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses. Bioconjug Chem. 19(7):1327–38.
[193]Park SW, Gwon HC, Jeong JO, Byun J, Kang HS, You JR, Cho SS, Lee MJ, Lee Y, Kim S, Kim DK. 2001. Intracardiac echocardiographic guidance and monitoring during percutaneous endomyocardial gene injection in porcine heart. Hum Gene Ther. 12(8):893–903.
[194]Parks RJ, Chen L, AntonM, SankarU, RudnickiMA, GrahamFL. 1996. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A. 93(24):13565–70.
[195]Pathak A, Patnaik S, Gupta KC. 2009. Recent trends in non-viral vector-mediated gene delivery. Biotechnol J. 4(11):1559–72.
[196]Plank C, Anton M, Rudolph C, Rosenecker J, Krötz F. 2003. Enhancing and targeting nucleic acid delivery by magnetic force. Expert Opin Biol Ther. 3(5):745–58.
[197]Potter H, Weir L, Leder P. 1984. Enhancer dependent expression of human kappa immunoglobulin genes introduced into mouse pre-B lymphocytes by electroporation. Proc Natl Acad Sci U S A. 81(22):7161–5.
[198]Power AT, Bell JC. 2007. Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer. Mol Ther. 15(4):660–5.
[199]Prausnitz MR, Mikszta JA, Cormier M, Andrianov AK. 2009. Microneedle-based vaccines. Curr Top Microbiol Immunol. 333:369–93.
[200]Qiao C, Li J, Zheng H, Bogan J, Li J, Yuan Z, Zhang C, Bogan D, Kornegay J, Xiao X. 2009. Hydrodynamic limb vein injection of adeno-associated virus serotype 8 vector carrying canine myostatin propeptide gene into normal dogs enhances muscle growth. Hum Gene Ther. 20(1):1–10.
[201]Recillas-Targa F. 2006. Multiple strategies for gene transfer, expression, knockdown, and chromatin influence in mammalian cell lines and transgenic animals. Mol Biotechnol. 34(3):337–354.
[202]Roberts LK, Barr LJ, Fuller DH, McMahon CW, Leese PT, Jones S. 2005. Clinical safety and efficacy of a powdered hepatitis B nucleic acid vaccine delivered to the epidermis by a commercial prototype device. Vaccine. 23(40):4867–78.
[203]Rodriguez D, Zhou Y, Rodriguez JR, Durbin RK, Jiminez V, McAllister WT, Esteban M. 1990. Regulated expression of nuclear genes by T3 RNA polymerase and lac repressor, using recombinant vaccinia virus vectors. J Virol. 64(10):4851–7.
[204]Rodriguez JF, Smith GL. 1990. Inducible gene expression from vaccinia virus vectors. Virology. 177(1):239–250.
[205]Rowe WP, Huebner RJ, Gilmore LK, Parrott RH, Ward TG. 1953. Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc Soc Exp Biol Med. 84(3):570–3.
[206]Rudolph C, Lausier J, Naundorf S, Müller RH, Rosenecker J. 2000. In vivo gene delivery to the lung using polyethylenimine and fractured polyamidoamine dendrimers. J Gene Med. 2(4):269–78.
[207]Schaffert D, Wagner E. 2008. Gene therapy progress and prospects: synthetic polymer-based systems. Gene Therapy 15(16):1131–8.
[208]Schatzlein AG, Zinselmeyer BH, Elouzi A, Dufes C, Chim YT, Roberts CJ, Davies MC, Munro A, Gray AI, Uchegbu IF. 2005. Preferential liver gene expression with polypropylenimine dendrimers. J Control Release. 101(1-3):247–58.
[209]Scherer F, Anton M, Schillinger U, Henke J, Bergemann C, Krüger A, Gänsbacher B, Plank C. 2002. Magnetofection: enhancing and targeting gene delivery by magnetic force in vitro and in vivo. Gene Ther. 9(2):102–9.
[210]Schiedner G, Hertel S, Johnston M, Biermann V, Dries V, Kochanek S. 2002. Variables affecting in vivo performance of high-capacity adenovirus vectors. J Virol. 76(4):1600–9.
[211]Schiedner G, Morral N, Parks RJ, Wu Y, Koopmans SC, Langston C, Graham FL, Beaudet AL, Kochanek S. 1998. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet. 18(2):180–3.
[212]Schillinger U, Brill T, Rudolph C, Huth S, Gersting S, Krötz F, Hirschberger J, Bergemann C, Plank C. 2005. Advances in magnetofection—magnetically guided nucleic acid delivery. J Magn Magn Mater. 293(1):501–8.
[213]Schmidt-Wolf GD, Schmidt-Wolf IGH. 2003. Non-viral and hybrid vectors in human gene therapy: an update. TRENDS in Molecular Medicine 9(2):67-72.
[214]Schnepp BC, Jensen RL, Chen CL, Johnson PR, Clark KR. 2005. Characterization of adeno-associated virus genomes isolated from human tissues. J Virol. 79(23):14793–803.
[215]Sessa G, Weissmann G. 1968. Phospholipid spherules (liposomes) as a model for biological membranes. J. Lipid Res. 9(3):310–8.
[216]Shah AC, Benos D, Gillespie GY, Markert JM. 2003. Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. J Neurooncol. 65(3):203–26.
[217]Sharma A, Li X, Bangari DS, Mittal SK. 2009. Adenovirus receptors and their implications in gene delivery.Virus Res. 143(2):184–94.
[218]Shen ZP, Brayman AA, Chen L, Miao CH. 2008. Ultrasound with microbubbles enhances gene expression of plasmid DNA in the liver via intraportal delivery. Gene Ther. 15(16):1147–55.
[219]Sheyn D, Kimelman-Bleich N, Pelled G, Zilberman Y, Gazit D, Gazit Z. 2008. Ultrasound-based nonviral gene delivery induces bone formation in vivo. Gene Ther. 15(4):257–66.
[220]Shi W, Arnold GS, Bartlett JS. 2001. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cellsurface receptors. Hum Gene Ther. 12(14):1697–711
[221]Shimamura M, Sato N, Taniyama Y, Kurinami H, Tanaka H, Takami T, Ogihara T, Tohyama M, Kaneda Y, Morishita R. 2005. Gene transfer into adult rat spinal cord using naked plasmid DNA and ultrasound microbubbles. J Gene Med. 7(11):1468–74.
[222]Shimamura M, Sato N, Taniyama Y, Yamamoto S, Endoh M, Kurinami H, Aoki M, Ogihara T, Kaneda Y, Morishita R. 2004. Development of efficient plasmid DNA transfer into adult rat central nervous system using microbubble-enhanced ultrasound. Gene Ther. 11(20):1532–9.
[223]Si Y, Pulliam AC, Linka Y, Ciccone S, Leurs C, Yuan J, Eckermann O, Fruehauf S, Mooney S, Hanenberg H, Clapp DW. 2008. Overnight transduction with foamyviral vectors restores the longterm repopulating activity of Fancc−/− stem cells. Blood. 112(12):4458–65.
[224]Simões S, Filipe A, Faneca H, Mano M, Penacho N, Düzgünes N, de Lima MP. 2005. Cationic liposomes for gene delivery. Expert Opin Drug Deliv. 2(2):237–54.
[225]Siu T, Trivedi DM, Chiao M, Rohling R. 2005. MEMS-based sonoporation devices for intratumoral gene therapy. The 13th International Conference on Solid-State Sensors, Actuators and Microsystems 1:205–8.
[226]Smith GL, Mackett M. 1992. The design, construction, and use of vaccinia virus recombinants. In Recombinant Poxviruses (Binns, M. M. and Smith, G. L., eds.) CRC Press, Boca Raton, 81–122.
[227]Smith GL. 1991. Vaccinia virus vectors for gene expression. Curr Opin Biotechnol. 2(5):713–7.
[228]Smith RH. 2008. Adeno-associated virus integration: virus versus vector. Gene Ther. 15(11):817–22.
[229]Somia N, Verma IM. 2000. Gene therapy: trials and tribulations. Nat Rev Genet. 1(2):91–9.
[230]Sonoda S, Tachibana K, Uchino E, Okubo A, Yamamoto M, Sakoda K, Hisatomi T, Sonoda KH, Negishi Y, Izumi Y, Takao S, Sakamoto T. 2006. Gene transfer to corneal epithelium and keratocytes mediated by ultrasound with microbubbles. Invest Ophthalmol Vis Sci. 47(2):558–64.
[231]Sorgi FL, Bhattacharya S, Huang L. 1997. Protamine sulfate enhances lipid-mediated gene transfer. Gene Ther. 4(9):961–8.
[232]Spergel JM, Chen-Kiang S. 1991. Interleukin 6 enhances a cellular activity that functionally substitutes for E1A protein in transactivation. Proc Natl Acad Sci U S A. 88(15):6472–6.
[233]Spergel JM, Hsu W, Akira S, Thimmappaya B, Kishimoto T, Chen-Kiang S. 1992. NF-IL6, a member of the C/EBP family, regulates E1A-responsive promoters in the absence of E1A. J Virol. 66(2):1021–30.
[234]Staal FJ, Pike-Overzet K, Ng YY, van Dongen JJ. 2008. Sola dosis facit venenum. Leukemia in gene therapy trials: a question of vectors, inserts and dosage? Leukemia. 22(10):1849–52.
[235]Staba MJ, Wickham TJ, Kovesdi I, Hallahan DE. 2000. Modifications of the fiber in adenovirus vectors increase tropism for malignant glioma models. Cancer Gene Ther. 7(1):13–9.
[236]Stachler MD, Bartlett JS. 2006. Mosaic vectors comprised of modified AAV1 capsid proteins for efficient vector purification and targeting to vascular endothelial cells. Gene Ther. 13(11):926–31.
[237]Stieger K, Belbellaa B, Le Guiner C, Moullier P, Rolling F. 2009. In vivo gene regulation using tetracycline-regulatable systems.Adv Drug Deliv Rev. 61(7-8):527–41
[238]Stomatos NM, Chakrabarti S, Moss B, Hare JD. 1987. Expression of polyomavirus virion proteins by a vaccinia virus vector: association of VP1 and VP2 with the nuclear framework. J. Virol. 61(2):516–25.
[239]Stone D, Lieber A. 2006. New serotypes of adenoviral vectors. Curr Opin Mol Ther. 8(5):423–31.
[240]Stopeck AT, Hersh EM, Akporiaye ET, Harris DT, Grogan T, Unger E, Warneke J, Schluter SF, Stahl S. 1997. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol. 15(1):341–9.
[241]Stopeck AT, Jones A, Hersh EM, Thompson JA, Finucane DM, Gutheil JC, Gonzalez R. 2001. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma. Clin Cancer Res. 7(8):2285–91.
[242]Suda T, Liu D. 2007. Hydrodynamic gene delivery: its principles and applications. Mol Ther. 15(12):2063–9.
[243]Suda T, Kamimura K, Kubota T, Tamura Y, Igarashi M, Kawai H, Aoyagi Y, Liu D. 2009. Progress toward liver-based gene therapy. Hepatol Res. 39(4):325–40.
[244]Suda T, Suda K, Liu D. 2008. Computer-assisted hydrodynamic gene delivery. Mol Ther. 16(6):1098–104.
[245]Suzuki R, Namai E, Oda Y, Nishiie N, Otake S, Koshima R, Hirata K, Taira Y, Utoguchi N, Negishi Y, Nakagawa S, Maruyama K. 2010. Cancer gene therapy by IL-12 gene delivery using liposomal bubbles and tumoral ultrasound exposure. J Control Release. 142(2):245–50.
[246]Suzuki R, Takizawa T, Negishi Y, Utoguchi N, Sawamura K, Tanaka K, Namai E, Oda Y, Matsumura Y, Maruyama K. 2008. Tumor specific ultrasound enhanced gene transfer in vivo with novel liposomal bubbles. J Control Release. 125(2):137–44.
[247]Sweeney P, Karashima T, Ishikura H, Wiehle S, Yamashita M, Benedict WF, Cristiano RJ, Dinney CP. 2003. Efficient therapeutic gene delivery after systemic administration of a novel polyethylenimine/DNA vector in an orthotopic bladder cancer model. Cancer Res. 63(14):4017–20.
[248]Talavera A, Rodriguez JM. 1991. Isolation and handling of recombinant vaccinia viruses. Practical Molecular Virology: Viral Vectors for Gene Expression 8:235–248.
[249]Tang MX, Redemann CT, Szoka FC Jr. 1996. In vitro gene delivery by degraded polyamidoamine dendrimers. Bioconjug Chem. 7(6):703–14.
[250]Taniyama Y, Tachibana K, Hiraoka K, Aoki M, Yamamoto S, Matsumoto K, Nakamura T, Ogihara T, Kaneda Y, Morishita R. 2002. Development of safe and efficient novel nonviral gene transfer using ultrasound: enhancement of transfection efficiency of naked plasmid DNA in skeletal muscle. Gene Ther. 9(6):372–80.
[251]Tata DB, Dunn F, Tindall DJ. 1997. Selective clinical ultrasound signals mediate differential gene transfer and expression in two human prostate cancer cell lines: LnCap and PC-3. Biochem Biophys Res Commun. 234(1):64–7.
[252]Thomas CE, Ehrhardt A, Kay MA. 2003. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 4(5):346–58.
[253]Timiryasova TM, Chen B, Fodor N, Fodor I. 2001. Construction of recombinant vaccinia viruses using PUV-inactivated virus as a helper. Biotechniques. 31(3):534, 536, 538-40.
[254]Todo T. 2008. “Armed” oncolytic herpes simplex viruses for brain tumor therapy. Cell Adh Migr. 2(3):208–13.
[255]Trobridge G, Josephson N, Vassilopoulos G, Mac J, Russell DW. 2002. Improved foamy virus vectors with minimal viral sequences. Mol Ther. 6(3):321–8.
[256]Trobridge GD. 2009. Foamy virus vectors for gene transfer. Expert Opin Biol Ther. 9(11):1427–36.
[257]Tsampoula X, Taguchi K, Cizmár T, Garces-Chavez V, Ma N, Mohanty S, Mohanty K, Gunn-Moore F, Dholakia K. 2008. Fibre based cellular transfection. Optics express 16(21):17007-13.
[258]Tsunoda H, Hayakawa T, Sakuragawa N, Koyama H. 2000. Site-specific integration of adenoassociated virus-based plasmid vectors in lipofected HeLa cells. Virology 268(2):391-401.
[259]Usdin TB, Brownstein MJ, Moss B, Isaacs SN. 1993. SP6 RNA polymerase containing vaccinia virus for rapid expression of cloned genes in tissue culture. Biotechniques 14(2):222–4.
[260]van Drunen Littel-van den Hurk S, Hannaman D. 2010. Electroporation for DNA immunization: clinical application. Expert Rev Vaccines. 9(5):503–17.
[261]Vasquez EC, Beltz TG, Meyrelles SS, Johnson AK. 1999. Adenovirus-mediated gene delivery to hypothalamic magnocellular neurons in mice. Hypertension 34(4 Pt 2):756-761.
[262]Verma IM, Weitzman MD. 2005. Gene therapy: twenty-first century medicine. Annu Rev Biochem. 74:711–38.
[263]Vigna E, Naldini L. 2000. Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J Gene Med. 2(5):308–16.
[264]Walther W, Stein U. 2000. Viral vectors for gene transfer a review of their use in the treatment of human diseases. Drugs. 60(2):249-71.
[265]Wang S, Joshi S, Lu S. 2004. Delivery of DNA to skin by particle bombardment. Methods Mol Biol. 245:185–96.
[266]Wang Z, Ma HI, Li J, Sun L, Zhang J, Xiao X. 2003. Rapid and highly efficient transduction by double-stranded adenoassociated virus vectors in vitro and in vivo. Gene Ther. 10(26):2105–11.
[267]Ward GA, Stover CK, Moss B, Fuerst TR. 1995. Stringent chemical and thermal regulation of recombinant gene expression by vaccinia virus vectors in mammalian cells. Proc Natl Acad Sci U S A 92(15):6773–7.
[268]Wells DJ. 2004. Gene therapy progress and prospects: electroporation and other physical methods. Gene Ther. 11(18):1363–9.
[269]White SJ, Nicklin SA, Buning H, Brosnan MJ, Leike K, Papadakis ED, Hallek M, Baker AH. 2004. Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors. Circulation. 109:513–9.
[270]Wickham TJ, Tzeng E, Shears LL 2nd, Roelvink PW, Li Y, Lee GM, Brough DE, Lizonova A, Kovesdi I. 1997. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J Virol. 71(11):8221–9.
[271]Wilson JM. 1996. Adenoviruses as gene-delivery vehicles. N Engl J Med. 334(18):1185–7.
[272]Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL. 1990. Direct gene transfer into mouse muscle in vivo. Science. 247(4949 Pt 1):1465–8.
[273]Woods NB, Muessig A, Schmidt M, Flygare J, Olsson K, Salmon P, Trono D, von Kalle C, Karlsson S. 2003. Lentiviral vector transduction of NOD/ SCID repopulating cells results in multiple vector integrations per transduced cell: risk of insertional mutagenesis. Blood. 101(4):1284–9.
[274]Wrenn SP, Dicker SM, Small EF, Dan NR, Mleczko M, Schmitz G, Lewin PA. 2012. Bursting bubbles and bilayers. Theranostics 2(12):1140-59.
[275]Wright JF, Qu G, Tang C, Sommer JM. 2003. Recombinant adenoassociated virus: formulation challenges and strategies for a gene therapy vector. Curr Opin Drug Discov Dev. 6(2):174–8.
[276]Xu K, Ma H, McCown TJ, Verma IM, Kafri T. 2001. Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors. Mol Ther. 3(1):97–104.
[277]Xu L, Huang CC, Huang W, Tang WH, Rait A, Yin YZ, Cruz I, Xiang LM, Pirollo KF, Chang EH. 2002. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol Cancer Ther. 1(5):337–46.
[278]Yager EJ, Dean HJ, Fuller DH. 2009. Prospects for developing an effective particle-mediated DNAvaccine against influenza. Expert Rev Vaccines. 8(9):1205–20.
[279]Yáñez-Muñoz RJ, Balaggan KS, MacNeil A, Howe SJ, Schmidt M, Smith AJ, Buch P, MacLaren RE, Anderson PN, Barker SE, Duran Y, Bartholomae C, von Kalle C, Heckenlively JR, Kinnon C, Ali RR, Thrasher AJ. 2006. Effective gene therapy with nonintegrating lentiviral vectors. Nat Med. 12(3):348–53.
[280]Yang GS, Schmidt M, Yan Z, Lindbloom JD, Harding TC, Donahue BA, Engelhardt JF, Kotin R, Davidson BL. 2002. Virus-mediated transduction of murine retina with adeno-associated virus: effects of viral capsid and genome size. J Virol. 76(15):7651–60.
[281]Yang NS, Burkholder J, Roberts B, Martinell B, McCabe D. 1990. In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. Proc Natl Acad Sci U S A. 87(24):9568–72.
[282]Yang Y, Li Q, Ertl HC, Wilson JM. 1995. Cellular and humoral immune responses to viral antigens create barriers to lungdirected gene therapy with recombinant adenoviruses. J Virol. 69(4):2004–15.
[283]Yang Y, Nunes FA, Berencsi K, Furth EE, Gönczöl E, Wilson JM. 1994a. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A. 91(10):4407–11.
[284]Yang Y, Nunes FA, Berencsi K, Gonczol E, Engelhardt JF, Wilson JM. 1994b. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet. 7(3):362–9.
[285]Yoshino H, Hashizume K, Kobayashi E. 2006. Naked plasmid DNA transfer to the porcine liver using rapid injection with large volume. Gene Ther. 13(24):1696–702.
[286]Yu RZ, Geary RS, Leeds JM, Watanabe T, Fitchett JR, Matson JE, Mehta R, Hardee GR, Templin MV, Huang K, Newman MS, Quinn Y, Uster P, Zhu G, Working PK, Horner M, Nelson J, Levin AA. 1999. Pharmacokinetics and tissue disposition in monkeys of an antisense oligonucleotide inhibitor of Ha-ras encapsulated in stealth liposomes. Pharm Res 16(8):1309–15.
[287]Zeira E, Manevitch A, Khatchatouriants A, Pappo O, Hyam E, Darash-Yahana M, Tavor E, Honigman A, Lewis A, Galun E. 2003. Femtosecond infrared laseran efficient and safe in vivo gene delivery system for prolonged expression. Mol Ther. 8(2):342–50.
[288]Zhang G, Budker V, Wolff JA. 1999. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther. 10(10):1735–7.
[289]Zhang G, Gao X, Song YK, Vollmer R, Stolz DB, Gasiorowski JZ, Dean DA, Liu D. 2004. Hydroporation as the mechanism of hydrodynamic delivery. Gene Ther. 11(8):675–82.
[290]Zhang Q, Yu YA, Wang E, Chen N, Danner RL, Munson PJ, Marincola FM, Szalay AA. 2007. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res. 67(20):10038–46.
[291]Zhang Y, Yu LC. 2008. Single-cell microinjection technology in cell biology. BioEssays 30(6):606–610.
[292]Zhou X, Huang L. 1994. DNA transfection mediated by cationic liposomes containing lipopolylysine: characterization and mechanism of action. Biochim Biophys Acta. 1189(2):195–203.
[293]Zou L, Zhou H, Pastore L, Yang K. 2000. Prolonged transgene expression mediated by a helper-dependent adenoviral vector (hdAd) in the central nervous system. Mol Ther. 2(2):105–13.
[294]Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. 1997. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol. 15(9):871–5.
[295]沈朋志博士 基因轉殖技術之應用 http://www.pabp.gov.tw/areabus/liba/
aa507.asp
[296]An Introduction to Transfection Methods. 2007. pp.1-8. http://bio.lonza.com/fileadmin/groups/marketing/DMS/downloads/TechRefGuide_AnIntroTransMeth.pdf
[297]Gene therapy clinical trials worldwide [online]. The Journal of Gene Medicine. 2011. Available from URL: http://www.wiley.com/legacy/wileychi/genmed/clinical/
[298]http://what-when-how.com/molecular-biology/transfection-molecular-biology/
[299]http://www.brl.uiuc.edu/Projects/sonoporation.php
[300]http://www.genetherapynet.com/viral-vectors/vaccinia-viruses.html
[301] http://www.ncku.edu.tw/~cbst/core_lab/equip/
core_nucleofector.htm
|